Biogen, Drugmaker Settle Angiomax Patent Royalties Row
Biogen Inc. has settled a licensing dispute in a New Jersey federal court with a pharmaceutical company over whether the global biotech giant could keep collecting royalties on sales of the...To view the full article, register now.
Already a subscriber? Click here to view full article